The EQ-5D-Y (Youth) in the Asia-Pacific: what is it, how to get it, and how to use it?

The Workshop of Virtual ISPOR Asia Pacific Summit 2022

Discussion Leader: Dr. Nan Luo

Discussants:

Prof. Dr. Jan van Busschbach, Dr. Zhihao Yang

Secretaries:

Wenjing Zhou

Yifan Ding

Guangjie Zhang

20 September 2022

GROUP HAS DEVEN

EUROGOL (

FO-5D-3

CHILDREN AND ADOLES

Speakers



Dr. Nan Luo

- Leader Discussant
- Domain Leader of Health Systems & Behavioural Sciences; Saw Swee Hock School of Public Health; National University of Singapore



Prof. Dr. Jan van Busschbach

- Discussant
- Head of section Medical Psychology
- Department of Psychiatry, Section Medical Psychology and Psychotherapy, Erasmus University Rotterdam



Dr. Zhihao Yang

- Discussant
- Health Services Management Department, Guizhou Medical University, China



Ms. Wenjing Zhou

- Speaker
- Pediatrician Physician; PhD student;
- Shanghai Renji Hospital, China; Department of Psychiatry, Erasmus University Rotterdam



Objective



EQ-5D-Y (a child-friendly version of EQ-5D), an internationally developed PROM, is designed for use in both clinical research and health economics

- To share experiences of using EQ-5D-Y in the Asia-Pacific region
- To help researchers and users to incorporate the instrument into their studies






Agenda

Time	Min	Торіс	Discussant		
11:45-11:50	5	Opening Remarks:Introduction of the speakersBrief outline and objectives	Nan Luo		
11:50 - 12:16	26	 Video 1 to Video 4 <u>1 or 2 polling questions</u> after each video 	Discussed by Nan Luo and Zhihao Yang Presented by Wenjing Zhou		
12:16 -12:21	5	EQ-5D-Y validation studies in Asia	Nan Luo		
12:21 – 12:26	5	• EQ-5D-Y valuation studies in Asia	Zhihao Yang		
12:26 – 12:45	19	Q&AClosing Remarks	Jan Busschbach		



Polling Questions

- Close-ended question with 4 to 5 response options
- Participants selecting the best answer based on their understanding of the videos
- A bar chart showing the participants' responses.
- Discussants explaining the answers and addressing any questions from the participants







Video 1 — What is EQ-5D-Y?



Measuring health-related quality of life in children and adolescents: The EQ-5D-Y

Ш

• 0:01 / 4:08

Measuring health-related quality of life in children and adolescents: The EQ-5D-Y



A



Polling Question for Video 1



Polling Questions – Video 1



- Which one of the following statements is NOT correct?
 - ✓ 5D means five dimensions: mobility, looking after myself, doing usual activity, having pain/discomfort, feeling worried/sad/unhappy.
 - ✓ 3L means three functional levels of for each dimension.
 - The two parts of the EQ-5D-Y questionnaire, i.e. the five dimensions and the EQ VAS can be used separately.
 - ✓ The recommended age range for using EQ-5D-Y (self-complete version) is 8 to 15 years.

• What can EQ-5D-Y be used for?

- ✓ To measure outcomes of health care interventions
- ✓ To monitor population health
- ✓ To assess routine clinical care
- ✓ To inform economic evaluation decisions
- ✓ All the above





Video 2 — How to obtain EQ-5D-Y instrument?







Þ

k





-



Polling Question for Video 2



Polling Questions – Video 2



- Which one of the following statements regarding the license fee for using the EQ-5D-Y is MOST accurate?
 - The size of the license fee depends on the nature of study, funding source, sample size, and the number of requested language versions.
 - EQ-5D-Y can be used free of charge for academic, educational, public health, and commercial purposes.
 - ✓ Licensing fees are not determined by the EuroQol Office.
 - ✓ EuroQol charges a license fee of EQ-5D.





Video 3 — Which mode of administration to use?





Modes of administration

EQ-5D-3L available modes of administration					
Self-complete versions	Interview versions				
• Paper	Face-to-face				
PDA/Smartphone	• Telephone				
• Tablet	Proxy versions				
Laptop/Desktop	 Proxy version 1 (Paper)^a 				
	 Proxy version 2 (Paper)^b 				







Polling Question for Video 3





Polling Questions – Video 3

- Which EQ-5D version should you use in children aged 8 to 12?
 - ✓ EQ-5D-3L
 - ✓ EQ-5D-5L
 - ✓ EQ-5D-Y
 - ✓ EQ-5D-Y proxy





Video 4 — How to Value Children's Health States?



How to Value Children's Health States?



5 dimensions, 3 levels of severity in each dimension

- Level 1: no problem
- Level 2: some problems
- Level 3: a lot of problems





Polling Question for Video 4



Polling Questions – Video 4



- If the EQ-5D-Y value sets for a specific country/region is not available yet, what is the second best option?
 - ✓ Do not use it for economic evaluations of healthcare interventions
 - ✓ Use the sum score of the levels over the dimensions
 - ✓ Use the adult EQ-5D-3L value set to calculate the EQ-5D-Y index value
 - ✓ Use the EQ-5D-Y value set of another country/region which has a similar culture





EQ-5D-Y validation studies in Asia

– Nan Luo



Validation Studies



- Aiming to evaluate the measurement properties of a quality-of-life instrument before formal use of the instrument
- Necessary when an instrument is introduced into a new population through translation or cultural adaptation
- Requires collection of individual-level data using the instrument from samples of the target population
- Measurement properties relevant to EQ-5D-Y
 - Validity
 - Reliability
 - Responsiveness





Erasmus MC

zalus

EQ-5D-Y validation studies in Asia: an overview

Version	Country	Year	Population/disease (mean age)	Validity	Reliability	Responsiveness
EQ-5D-Y	China	2021	Urban pupils (12.7±3.1)	V		
EQ-5D-Y-5L	China	2021	Urban pupils (12.7±3.1)	V		
EQ-5D-Y	China	2020	Rural pupils (8.7±0.61)	V		
EQ-5D-Y	China	2021	Haematological malignancies (10.5±2.2)		V	
EQ-5D-Y-5L	China	2021	Haematological malignancies (10.5±2.2)		V	
EQ-5D-Y	Hong Kong	2019	Idiopathic scoliosis (14.0±1.9)	V	V	V
EQ-5D-Y-5L	Hong Kong	2019	Idiopathic scoliosis (14.0 \pm 1.9)	V	V	V
EQ-5D-Y	Taiwan	2018	Chronic kidney disease (12.0±4.1)	V	V	
EQ-5D-Y	South Korea	2018	Allergy symptoms (10.2±1.8)	V		
EQ-5D-Y	Japan	2019	Pupils (11.0)	V	V	
EQ-5D-Y	Indonesia	2021	Beta-thalassemia, Haemophilia, Acute	V	V	V
EQ-5D-Y-5L	Indonesia	2021	lymphoblastic leukaemia, Acute illness (11.2±2.4)	V	V	V
EQ-5D-Y	Thailand	2020	Thalassemia (9.1±4.3)	V		





EQ-5D-Y valuation studies in Asia

– Zhihao Yang





EQ-5D-Y valuation studies in Asia

Published	Data collection finished	Data collection on-going
Japan	China	Singapore
	Indonesia	Malaysia
	Vietnam	Hong Kong
		Taiwan





To conduct an EQ-5D-Y valuation study in your country

Rule of thumbs:

1. Understand the need.

- What is the HTA environment? What does the Pharmacoeconomic evaluation guide suggest?
- 2. Engage with local HTA body.
 - Can you obtain local fund? Do they have suggestions for this study?
- 3. Is EQ-5D-Y available in your language? Has it been validated?
 - Check the FAQ section: <u>https://euroqol.org/eq-5d-instruments/eq-5d-y-about/faqs/</u>
- 4. Read the EQ-5D-Y valuation protocol, evaluate the feasibility of conducting a valuation study.
 - E.g., how to recruit a representative sample in your country?
 - Is online DCE survey possible?

5. Always contact EuroQol first. For EQ-5D-Y valuation, you can contact the Youth population working group, please see: (<u>https://euroqol.org/euroqol/working-groups/eq-5d-in-younger-populations/</u>)







You have Questions

We have Answers



Contact Information: ephln@nus.edu.sg Nan Luo: Jan Busschbach: j.vanbusschbach@erasmusmc.nl Zhihao Yang: Zhihao yang cn@outlook.com